PHAR: Pharming Group N.V. Growth-Adjusted Market Cap to Net Income

Pharming Group N.V. relies on diversified cold-chain logistics, which ensures the integrity of biological products and stable margins. The P/E ratio relative to business expansion rates visualizes market value against growth dynamics, where the value 0.23 reflects the metric's balance. High physician confidence in the brand within the rare disease sector is complemented by patent protection for Ruconest, which precludes the rapid entry of generics.

The PEG ratio compares the P/E multiple with net income growth rates, allowing investors to determine if they are overpaying for business momentum. By analyzing the alignment of the P/E ratio with growth rates, one can assess the fair value of Pharming Group N.V. (PHAR) considering the sales expansion of its patented biopharmaceutical drugs for the therapy of rare pathologies.